Bread for celiac vaccine

ImmusanT banks $20M based on celiac immunotherapy's T cell response

Bread for celiac vaccine

ImmusanT Inc. is working on a peptide-based therapeutic vaccine designed to address the underlying problem in celiac disease, and received $20 million in

Read the full 268 word article

How to gain access

Continue reading with a
two-week free trial.